Coagadex approved for rare clotting disorder

(HealthDay)—Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor X deficiency.

The Factor X protein normally helps blood clot. But among people with the inherited disorder, the blood doesn't clot, which can lead to dangerous bleeding episodes. Traditional treatments are based on plasma-derived products containing vitamin K-dependent proteins to stem or prevent bleeding, the agency said in a news release.

Coagadex, derived from human blood plasma, has been approved for people 12 years and older to control and prevent random bleeding episodes, and those stemming from menstruation or recent surgery.

The product was evaluated in clinical studies of 16 people with the rare disorder, which affects men and women equally. No safety concerns were identified in these studies, the FDA said.

Coagadex is manufactured by Bio Products Laboratory Ltd., based in the United Kingdom.

Explore further

Long-acting clotting agent approved for form of hemophilia

More information: Learn more about this approval from the FDA.

Copyright © 2015 HealthDay. All rights reserved.

Citation: Coagadex approved for rare clotting disorder (2015, October 21) retrieved 17 October 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors